KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Other Non-Current Assets (2019 - 2025)

Arbutus Biopharma's Other Non-Current Assets history spans 7 years, with the latest figure at $131000.0 for Q3 2025.

  • For Q3 2025, Other Non-Current Assets changed N/A year-over-year to $131000.0; the TTM value through Sep 2025 reached $131000.0, changed N/A, while the annual FY2024 figure was $34000.0, N/A changed from the prior year.
  • Other Non-Current Assets for Q3 2025 was $131000.0 at Arbutus Biopharma, up from $34000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $180000.0 in Q2 2022 and bottomed at $3000.0 in Q3 2023.
  • The 5-year median for Other Non-Current Assets is $61000.0 (2021), against an average of $80444.4.
  • The largest annual shift saw Other Non-Current Assets skyrocketed 68.85% in 2022 before it tumbled 98.2% in 2023.
  • A 5-year view of Other Non-Current Assets shows it stood at $61000.0 in 2021, then surged by 68.85% to $103000.0 in 2022, then crashed by 97.09% to $3000.0 in 2023, then skyrocketed by 1033.33% to $34000.0 in 2024, then skyrocketed by 285.29% to $131000.0 in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Other Non-Current Assets are $131000.0 (Q3 2025), $34000.0 (Q1 2025), and $34000.0 (Q4 2024).